P. E. Chung

Targeting HER2+ breast cancer: the TBK1/IKKε axis

S. Egan, Zhe Jiang, Jeffrey C. Liu, 2014, Oncoscience.

RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Gary D Bader, L. Muthuswamy, G. Pellecchia, 2016, The Journal of clinical investigation.

A racemosin B derivative, C25, suppresses breast cancer growth via lysosomal membrane permeabilization and inhibition of autophagic flux.

Y. Ben-David, P. E. Chung, E. Zacksenhaus, 2022, Biochemical pharmacology.

Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy

S. Croul, Benjamin Haibe-Kains, M. Remke, 2020, Nature Communications.

CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead

Zhe Jiang, Jeffrey C. Liu, P. E. Chung, 2018, Molecular & cellular oncology.